Potentially Life-Threatening Interaction between Opioids and Intrathecal Baclofen in Individuals with a Childhood-Onset Neurological Disorder: A Case Series and Review of the Literature

Abstract

Background Spasticity and dystonia are movement impairments that can occur in childhood-onset neurological disorders. Severely affected individuals can be treated with intrathecal baclofen (ITB). Concomitant use of ITB and opioids has been associated with central nervous system (CNS) depression. This study aims to describe the clinical management of this interaction, based on a case series and review of literature.

Methods Four individuals with childhood-onset CNS disorders (age 8–24) and CNS-depressant overdose symptoms after the concomitant use of ITB and opioids are described. The Drug Interaction Probability Scale (DIPS) was calculated to assess the cause-relationship (doubtful <2, possible 2–4, probable 5–8, and highly probable >8) of the potential drug–drug interaction. A literature review of similar previously reported cases and the possible pharmacological mechanisms of opioid–baclofen interaction is provided.

Results After ITB and opioid co-administration, three out of four patients had decreased consciousness, and three developed respiratory depression. DIPS scores indicated a possible cause-relationship in one patient (DIPS: 4) and a probable cause-relationship in the others (DIPS: 6, 6, and 8). Discontinuation or adjusting ITB or opioid dosages resulted in clinical recovery. All patients recovered completely. In the literature, two articles describing nine unique cases were found.

Conclusion Although the opioid–ITB interaction is incompletely understood, concomitant use may enhance the risk of symptoms of CNS-depressant overdose, which are potentially life-threatening. If concomitant use is desirable, we strongly recommend to closely monitor these patients to detect interaction symptoms early. Awareness and monitoring of the potential opioid–ITB interaction is essential to reduce the risk of severe complications.

Keywords

baclofen - opioids - respiratory depression - decreased consciousness - drug interaction

Authors Contributions

L.M.vD., A.vZ., and L.A.B. designed the study. L.M.vD., A.vZ., A.I.B., S.N.dW., and L.A.B. contributed to the investigation and writing of the original draft. L.M.vD., A.vZ., A.I.B., L.A.vdP., K.M.S., S.N.dW., and L.A.B. contributed to writing, reviewing, and editing. All authors have read and agreed to the published version of the manuscript.

Publikationsverlauf

Eingereicht: 06. Februar 2024

Angenommen: 22. April 2024

Artikel online veröffentlicht:
22. Mai 2024

• References

• 1 Klein C, Münchau A. Progressive dystonia. Handb Clin Neurol 2013; 113: 1889-1897
• 2 Brett E, Lake B. Progressive neurometabolic brain diseases. Pediatric Neurology 1997; 3: 143-200
• 3 Dyken P, Krawiecki N. Neurodegenerative diseases of infancy and childhood. Ann Neurol 1983; 13 (04) 351-364
• 4 Rosenbaum P, Paneth N, Leviton A. et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007; 109: 8-14
• 5 Buizer AI, Martens BHM, Grandbois van Ravenhorst C, Schoonmade LJ, Becher JG, Vermeulen RJ. Effect of continuous intrathecal baclofen therapy in children: a systematic review. Dev Med Child Neurol 2019; 61 (02) 128-134
• 6 Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol 1996; 11 (Suppl. 01) S29-S35
• 7 Milanov IG. Mechanisms of baclofen action on spasticity. Acta Neurol Scand 1992; 85 (05) 305-310
• 8 Bonouvrié LA, Becher JG, Vles JSH, Vermeulen RJ, Buizer AI, Group IS. IDYS Study Group. The effect of intrathecal baclofen in dyskinetic cerebral palsy: the IDYS trial. Ann Neurol 2019; 86 (01) 79-90
• 9 Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996; 11 (02) 77-83
• 10 Knutsson E, Lindblom U, Mårtensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 1974; 23 (03) 473-484
• 11 Albright AL, Shultz BL. Plasma baclofen levels in children receiving continuous intrathecal baclofen infusion. J Child Neurol 1999; 14 (06) 408-409
• 12 Francisco GE, Saulino MF, Yablon SA, Turner M. Intrathecal baclofen therapy: an update. PM R 2009; 1 (09) 852-858
• 13 Jain A, Sullivan BT, Shah SA. et al. Caregiver perceptions and health-related quality-of-life changes in cerebral palsy patients after spinal arthrodesis. Spine 2018; 43 (15) 1052-1056
• 14 Richtlijn Postoperatieve pijn [Internet]. 2012 . Accessed May 02, 2024 at: https://www.anesthesiologie.nl/
• 15 Kheder A, Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol 2012; 12 (05) 289-298
• 16 Yang J, Reilly BG, Davis TP, Ronaldson PT. Modulation of opioid transport at the blood-brain barrier by altered ATP-binding cassette (ABC) transporter expression and activity. Pharmaceutics 2018; 10 (04) 192
• 17 Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In Brunton L, Chabner B, Knollman B. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. Twelfth Edition. McGraw-Hill Professional; 2011: 481-526
• 18 Li Y, Delcher C, Wei YJ. et al. Risk of opioid overdose associated with concomitant use of opioids and skeletal muscle relaxants: a population-based cohort study. Clin Pharmacol Ther 2020; 108 (01) 81-89
• 19 Khan NF, Bykov K, Barnett ML, Glynn RJ, Vine SM, Gagne JJ. Comparative risk of opioid overdose with concomitant use of prescription opioids and skeletal muscle relaxants. Neurology 2022; 99 (13) e1432-e1442
• 20 Khan NF, Bykov K, Glynn RJ, Barnett ML, Gagne JJ. Coprescription of opioids with other medications and risk of opioid overdose. Clin Pharmacol Ther 2021; 110 (04) 1011-1017
• 21 Rizzo G, Bussolin L, Genitori L. et al. The use of opioids in children receiving intrathecal baclofen therapy. Childs Nerv Syst 2019; 35 (07) 1213-1218
• 22 Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41 (04) 674-680
• 23 Scheife RT, Hines LE, Boyce RD. et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf 2015; 38 (02) 197-206
• 24 Nederland Z. Farmacotherapeutisch Kompas. Accessed May 02, 2024 at: https://farmacotherapeutischkompas.nl
• 25 Anderson KJ, Farmer JP, Brown K. Reversible coma in children after improper baclofen pump insertion. Paediatr Anaesth 2002; 12 (05) 454-460
• 26 Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018; 9 (01) 63-88
• 27 Zieglgänsberger W, Howe JR, Sutor B. The Neuropharmacology of Baclofen. Local-Spinal Therapy of Spasticity. Springer; 1988: 37-49
• 28 Benarroch EE. GABAB receptors: structure, functions, and clinical implications. Neurology 2012; 78 (08) 578-584
• 29 Ghanavatian S, Derian A. Baclofen. 2018
• 30 Zöllner C, Stein C. Opioids. Handb Exp Pharmacol 2007; (177) 31-63
• 31 Watanabe JH, Yang J. Association of combination opioid, benzodiazepine, and muscle relaxant usage with emergency department visits in a nationwide cohort in the United States. Int J Clin Pharm 2021; 43 (02) 358-364
• 32 Gordon NC, Gear RW, Heller PH, Paul S, Miaskowski C, Levine JD. Enhancement of morphine analgesia by the GABAB agonist baclofen. Neuroscience 1995; 69 (02) 345-349
• 33 Pedrón VT, Varani AP, Bettler B, Balerio GN. GABA_B receptors modulate morphine antinociception: pharmacological and genetic approaches. Pharmacol Biochem Behav 2019; 180: 11-21
• 34 Wilkerson JL, Felix JS, Restrepo LF, Ansari MI, Coop A, McMahon LR. The effects of morphine, baclofen, and buspirone alone and in combination on schedule-controlled responding and hot plate antinociception in rats. J Pharmacol Exp Ther 2019; 370 (03) 380-389
• 35 Fridén M, Winiwarter S, Jerndal G. et al. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 2009; 52 (20) 6233-6243
• 36 Reichel A. Integrated approach to optimizing CNS penetration in drug discovery: from the old to the new paradigm and assessment of drug–transporter interactions. In: Hammarlund-Udenaes M, de Lange E, Thorne R. eds. Drug Delivery to the Brain. 10. New York, NY: Springer; 2014: 339-374
• 37 Bhargava HN, Villar VM, Rahmani NH, Larsen AK. Time course of the distribution of morphine in brain regions, spinal cord and serum following intravenous injection to rats of differing ages. Pharmacology 1993; 47 (01) 13-23
• 38 Kroin JS, Ali A, York M, Penn RD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery 1993; 33 (02) 226-230 , discussion 230
• 39 Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology 2000; 92 (03) 739-753
• 40 Hinrichs M, Weyland A, Bantel C. [Piritramide : A critical review]. Schmerz 2017; 31 (04) 345-352